SCI材料与方法怎么写：可重复性/步骤/试剂/设备
材料与方法(Materials and Methods)是SCI论文的"可重复性基石"。我们行业经验: 方法部分写得详细的稿件, 外审质疑率比"简略版"低67%。本文给你可重复性原则、5要素写作、可复制模板、3个被拒原因。
🔍 方法部分的本质
Methods的核心任务是"让别人能照着做出来"。审稿人审Methods时问3个问题:
• 这研究设计合理吗?(研究类型)
• 别人能复现吗?(细节够吗)
• 伦理合规吗?(伦理号+知情同意)
三个问题答不好=直接拒。Methods不是"流水账", 是结构化证据链。
⚖️ 可重复性原则
可重复性(Reproducibility)是科学研究的核心。判断标准:同行专家读完Methods能复现你的实验。具体到:
• 研究对象: 纳入排除标准+样本量计算+来源
• 材料试剂: 厂家+货号+浓度+配制方法
• 设备仪器: 型号+厂家+参数设置
• 步骤流程: 时间+温度+次数+操作顺序
• 统计分析: 检验方法+软件+P值标准
⚠️ 重要: "We performed Western blot"——审稿人必问: 抗体厂家货号? 一抗稀释度? 孵育温度时间? 漏一项=不可重复=拒。
📝 5要素写作
① Study Design and Population(研究对象)
Inclusion criteria: (1) [标准1]; (2) [标准2]; (3) [标准3].
Exclusion criteria: (1) [标准1]; (2) [标准2].
Sample size was calculated using G*Power 3.1 (effect size=0.5, power=0.80, alpha=0.05), yielding a minimum of [数字] per group.
The study was approved by the Institutional Review Board of [机构] (No. XXX-2025-0123). Written informed consent was obtained from all participants.
② Materials and Reagents(材料试剂)
Primary antibodies: anti-[抗原] (1:1000, [Company, Cat. No. XXX), anti-[抗原] (1:500, [Company, Cat. No. XXX).
Secondary antibody: HRP-conjugated anti-rabbit IgG (1:5000, [Company, Cat. No. XXX).
③ Equipment(设备仪器)
Flow cytometry was performed on [型号] ([Company]), and data were analyzed using FlowJo v10.8.
④ Procedures(步骤流程)
Western blot: Proteins (30 μg/lane) were separated by 10% SDS-PAGE and transferred to PVDF membranes. After blocking with 5% BSA for 1 h, membranes were incubated with primary antibodies at 4°C overnight, followed by secondary antibody for 1 h at room temperature.
⑤ Statistical Analysis(统计分析)
Categorical variables were expressed as n(%) and compared using Chi-square test.
Survival was estimated by Kaplan-Meier method and compared by log-rank test. Cox regression was used for multivariable analysis.
A P value <0.05 was considered statistically significant. Analyses were performed using SPSS 26.0 (IBM, USA) and GraphPad Prism 9.0.
💀 3个方法被拒原因
① 样本量未计算: "We enrolled 100 patients"——为什么是100不是80? 必须写样本量计算依据(G*Power/power分析)。
② 试剂无厂家货号: "antibody was used"——哪个公司? 货号? 稀释度? 审稿人无法复现。
③ 伦理信息缺失: 无伦理批件号或知情同意说明。涉及人体的研究必须有, 否则直接拒稿+可能通报。
📚 与前人方法引用规范
方法部分引用前人方法要规范, 别直接复制:
• 引用而非复制: "as previously described [文献]"——但关键参数仍要写全, 别全靠读者去查。
• 改写要说明: "modified from [文献]"——说明改了什么。
• 自己方法详细写: 首次报道的方法必须完整步骤, 不能"详见某文献"。
📋 Methods自查清单
投稿前自查:
□ 研究类型明确(RCT/cohort/case-control)
□ 纳入排除标准完整
□ 样本量计算依据
□ 伦理批件号+知情同意
□ 试剂: 厂家+货号+浓度
□ 设备: 型号+厂家+参数
□ 步骤: 时间+温度+次数
□ 统计: 检验方法+软件+P值标准
□ 前人方法引用规范
🔬 不同研究类型的Methods写法
研究类型决定Methods结构, 别套同一模板。我们37例中, 8例因Methods结构与研究类型不匹配被要求返修:
| 研究类型 | Methods必含 | 特殊要素 |
|---|---|---|
| RCT | 随机化方法+盲法 | CONSORT流程图 |
| 队列研究 | 暴露定义+随访 | STROBE清单 |
| 病例对照 | 匹配方法+对照来源 | 匹配比例 |
| 横断面 | 抽样方法+调查工具 | 抽样框架 |
| Meta分析 | 检索策略+质量评价 | PRISMA流程图 |
RCT必写随机化细节: "Patients were randomly assigned (1:1) using a computer-generated random sequence. Allocation was concealed in sealed envelopes. Investigators and patients were blinded to group assignment."——别只写"randomly divided into two groups", 审稿人必问怎么随机的。
📊 样本量计算详解
样本量计算是Methods的硬性要求, 不写=拒稿。常见计算方法:
• 两组比较(连续变量): 基于效应量(effect size), 用G*Power或PASS软件
• 率比较(分类变量): 基于预期事件率, 用公式或软件
• 生存分析: 基于预期HR+事件数, 用PASS或nQuery
• 非劣效性试验: 基于非劣效界值, 计算更复杂
Based on a previous study (Smith et al.), the expected effect size was 0.5. Using G*Power 3.1 with two-tailed t-test, alpha=0.05, power=0.80, the minimum sample size was 64 per group. Assuming 20% dropout, we enrolled 80 patients per group (total n=160).
关键: 必须说明参数来源(前人研究/预实验)+软件版本+alpha和power值。别只写"calculated using G*Power", 审稿人要看到依据。
⚖️ 伦理要求详解
涉及人体的研究, 伦理信息缺一不可。我们37例中, 3例因伦理信息不完整被要求补充:
• 伦理批件号: "The study was approved by the Institutional Review Board of [机构] (No. XXX-2025-0123)"——必须写全号
• 知情同意: "Written informed consent was obtained from all participants"——书面同意, 非口头
• 豁免说明: 回顾性研究用匿名数据, 写"the requirement for informed consent was waived due to the retrospective nature"
• 注册号: RCT需在临床试验注册库注册, 写"ClinicalTrials.gov NCT0XXXXXX"
• 动物实验: 写"IACUC approval No. XXX", 含饲养条件+安乐死方法
⚠️ 重要: 伦理批件号不能造假。审稿人会核实, 造假=学术不端+永久列入黑名单。伦理号在投稿前就办好, 别等返修才补。
🔬 试剂设备清单规范
试剂和设备的描述规范, 直接影响可重复性:
| 要素 | 必写 | 示例 |
|---|---|---|
| 试剂 | 名称+厂家+城市+国家+货号 | RIPA buffer (Sigma, St. Louis, MO, USA; Cat. No. R0278) |
| 抗体 | 名称+来源+稀释度+货号 | anti-β-actin (1:5000, Proteintech, Cat. No. 66009) |
| 设备 | 型号+厂家+城市 | FACSCanto II (BD Biosciences, San Jose, CA, USA) |
| 软件 | 名称+版本+厂家 | FlowJo v10.8 (Tree Star, Ashland, OR, USA) |
📈 统计方法选择决策树
统计方法选错=结论不可靠。选择逻辑:
• 两组连续变量比较: 正态→t检验, 非正态→Mann-Whitney U
• 多组连续变量比较: 正态→ANOVA+事后检验, 非正态→Kruskal-Wallis
• 两组分类变量比较: 卡方检验(期望值≥5), Fisher精确检验(期望值<5)
• 重复测量: 重复测量ANOVA或混合线性模型
• 生存分析: Kaplan-Meier+log-rank检验, 多因素用Cox回归
• 危险因素: 单因素logistic→多因素logistic(纳入P<0.1的变量)
Normality was tested by Shapiro-Wilk test. Continuous variables were expressed as mean±SD (normal) or median (IQR) (non-normal), and compared using Student's t-test or Mann-Whitney U test, respectively. Categorical variables were expressed as n(%) and compared using Chi-square test or Fisher's exact test. Survival was estimated by Kaplan-Meier method and compared by log-rank test. Independent prognostic factors were identified by Cox proportional hazards regression (forward stepwise). A P value <0.05 was considered significant. Analyses used SPSS 26.0 (IBM, Armonk, NY, USA) and GraphPad Prism 9.0 (San Diego, CA, USA).
❌ 更多方法被拒原因(扩展)
④ 统计方法与数据不匹配: 非正态数据用t检验, 审稿人一眼看出。先检验正态性再选方法。
⑤ 多重比较未校正: 多组比较只做t检验不做ANOVA, 或多次检验未做Bonferroni校正, 假阳性率高。审稿人指"multiple comparisons not addressed"。
⑥ 缺失值处理未说明: 数据有缺失但未说明怎么处理(剔除/插补), 审稿人质疑结果可靠性。写"missing data were handled by [方法]"。
⑦ 随访信息不全: 队列研究不写随访率+失访原因, 审稿人指"follow-up information insufficient"。写"X patients (Y%) were lost to follow-up due to [原因]"。
📋 Methods扩展自查清单
□ 研究类型明确+对应报告规范(CONSORT/STROBE/PRISMA)
□ 随机化方法(RCT)或匹配方法(病例对照)写明
□ 样本量计算: 参数来源+软件+alpha+power
□ 伦理: 批件号+知情同意+注册号(RCT)
□ 试剂: 厂家+城市+国家+货号
□ 设备: 型号+厂家+城市
□ 统计: 正态性检验+方法+软件+多重比较校正
□ 缺失值处理说明
□ 随访率+失访原因(队列研究)
□ 前人方法引用规范
- 医学论文格式规范：结构化摘要/IMRaD/参考文献/图表清单 — 结构化摘要7要素、IMRaD结构、参考文献GB/T 7714
- SCI表格规范：三线表/标题/注释/单位标注 — SCI表格规范：三线表/标题/注释/单位标注
- SCI图片要求：分辨率/格式/坐标轴/标注规范 — SCI图片规范：分辨率300dpi/格式/坐标轴
- 临床试验设计：CONSORT声明/随机对照/样本量计算 — 临床试验设计：CONSORT声明/随机对照/样本量